Gli oppioidi sono indicati nel dolore neuropatico no
1 / 34

Gli oppioidi sono indicati nel dolore neuropatico ? NO - PowerPoint PPT Presentation

  • Uploaded on

“ Controversie sulla diagnosi e terapia del dolore neuropatico ” Opinioni a confronto. Gli oppioidi sono indicati nel dolore neuropatico ? NO . Marco Lacerenza Medicina del Dolore Fondazione “Opera San Camillo” Casa di Cura S. Pio X, Milano.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about ' Gli oppioidi sono indicati nel dolore neuropatico ? NO ' - dagmar

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Gli oppioidi sono indicati nel dolore neuropatico no

Controversie sulla diagnosi

e terapia del dolore neuropatico”

Opinioni a confronto

Glioppioidisonoindicatineldoloreneuropatico? NO

Marco Lacerenza

Medicina del Dolore

Fondazione “Opera San Camillo”

Casa di Cura S. Pio X, Milano

Palermo, 29-30 novembre 2012, Reale Albergo delle Povere



  • RCT, Linee Guida…………..artefatti della medicina moderna che danno DATI UTILISSIMI MA………….

  • Possono subire le influenze di forze non utili al nostro fine

  • Possono facilitare le generalizzazioni

  • possono facilitare la medicina della INDICAZIONE senza valutazione

  • sedano l’ansia del giovane medico e accorciano le visite dell’esperto

  • Proteggono dal pdv medico legale

  • Smettiamola di parlare di “Dolore Neuropatico”

  • Parliamo di Pazienti SOFFERENTI, con dolore spesso neuropatico, cronico, complessi, con molte comorbidità

  • Ognuno diverso dall’altro, con scarsa QoL e problemi famigliari, lavorativi, economici

Dolore - Sofferenza

“Tra i rimedi che

Dio Onnipotente ha voluto, bontà Sua, dare all’uomo per alleviare

le sue sofferenze, nessuno è universale

ed efficace come l’oppio.”

Thomas Sydenham, 1624-1689

Sumeri: IX secolo AC: oppio la pianta della gioia

Omero, IV libro Odissea :….“Nel dolce Vino, di cui bevean, farmaco infuse contrario al pianto e all'ira, e che l'obblìo seco inducea d'ogni travaglio e cura”.

GaspareTraversi 1753




Distinctroles in hedonichomeostasis and emotionalcontrol









Individuals with high reward responsiveness, a personality trait dependent on the endogenous opioid neurotransmission, experience more exogenous opioid-induced behavioral analgesia.

Emergingevidencesuggests that MOR polymorphism could contribute to variability in behavioral opioid analgesia by introducing variability of the MOR responsiveness to exogenous opioids.

It is possible that trait RWR and the neuronal response to noxious stimuli in the endogenous opioid-rich brain reward circuitry could be useful endophenotypes of behavioral opioid analgesia.

Localizzazione dei recettori per gli oppioidi
Localizzazione dei trait dependent on the endogenous recettori per gli oppioidi

Corteccia cingolata anteriore, C.prefrontale, strati superficiali della corteccia cerebrale

Nuclei della base, talamo, amigdala,

PAG, RMN, reticolare del tronco

Corno posteriore midollare:

  • proiezioni midollari afferenti primari

  • Interneuroni midollari

    Periferia: nocicettori e afferenti viscerali

Legame Presinaptico trait dependent on the endogenous

Oppioidi: Meccanismi d’azione


Blocco ingresso ioni Ca++



Recettori oppioidi

Fuoriuscita di ioni K+

Fuoriuscita di ioni K+

Modificata da: A.H.Dickenson, 2000

I trait dependent on the endogenous recettori per glioppioidi

I trait dependent on the endogenous recettori per glioppioidi: binding

Perché funzionano poco???? trait dependent on the endogenous

Nerve-injury neuropathy and Diabetic Neuropathy:

Functionaldownregulation and/or desensitizationof μ-opioid receptors in the dorsal horn of the spinal cord (but not a significant decrease in number) may be related to increased production of PKC .

May be due to: activation of NMDARs in postsynaptic cells,

to an autophosphorylation of the TrkB receptor by BDNF.

In fact, the development of the hyperalgesia and allodynia in NP states is suppressed by

administration of NMDA receptor antagonists,

TrkB/Fc chimera protein (sequesters endogenous BDNF)

PKC inhibitors.

Dolore Neuropatico: trait dependent on the endogenous Meccanismi che portano alla desensitizzazione di MORs

Ridotta efficacia nella pratica clinica

  • Genetic mechanisms trait dependent on the endogenous

  • Sensitiz. ofprimaryafferent N.

  • Central Glutamatergic system

  • Descending facilitation (in RVM on-cells and CCK) leading to up-regulation of Spinal dynorphin and enhanced primary afferent neurotransmitter release (CGRP) and pain.

  • Decreased reuptake of neurotransmitters from the primary afferent fibers

Pain that has become more diffuse and less defined in quality and has a wider spatial distribution than the pre-existingpain.

NMDA receptors become activated and when inhibited, prevent the development of tolerance

and OIH

The glutamate transporter system is inhibited,

(increasing the amount of glutamate available to NMDAR)

Ca regulated intracellular PKC is likely a link between cellular mechanisms of tolerance and OIH

Prolongedmorphineadministrationinducesneurotoxicityvia NMDA receptor mediated apoptotic cell death in the dorsal horn

Smith HS, 2012 trait dependent on the endogenous

Il risveglio americano dall’ trait dependent on the endogenous oppiofobia

“Opioidmaintenancetherapy can be a safesalutary and more humanealternative… thosepatientswithintractablenon-malignantpain and non historyofdrugabuse”

The dichotomous classification of trait dependent on the endogenous nociceptive and neuropathic pain is not yet fully recognized in the pain literature or among physicians dealing withpain.

..comonnarcoticanalgesics, administered in a double-blind fashion and in doses which effectively control acute and

chronic nociceptive pain, are inefficient for relief of neuropathic (including deafferentation) pain…..

The reason ………..isunknown.

Opioids for neuropathic pain trait dependent on the endogenous (Review), 2009

Eisenberg E, McNicol ED, Carr DB

Short-term studies: equivocal evidence regarding the efficacy of opioids in neuropathic pain.

Intermediate-term studies demonstrated significant efficacy of opioids over placebo for neuropathic pain.

The difference in outcomes does not support the use of short-term opioid administration as a predictive tool to decide whether to initiate intermediate-term opioid therapy.

…the participants in the included studies may not reflect those commonly seen in practice. Therefore, issues such as abuse of medication, or conversely, non-compliance due to participants’ unwillingness to tolerate side effects may not be accurately reflected in our results.

The meta-analysis of Martell et al. 2007 identifies also a number of relevant issues:

patients were more likely to be prescribed opioids if they reported greater distress and suffering.

The prevalence of substance abuse disorders was in the range of 40% to 50% in these patients and up to 24% showed aberrantmedication-takingbehaviour

Long-term trials of opioid efficacy for chronic back pain are lacking, and there is other evidence that indicates that the long-term efficacy of opioids for chronic pain may be limited

Opioids number of relevant issues: and opioid combinations were exceeding NSAIDs in proportion of patients and number of prescriptions.

Short-acting opioids are frequently used as rescue medication…. high prescribing..(36.5%). Although the frequency of use of long-acting opioids was low (3.8%), the median (7.0) number of prescriptions were higher than for any other medication.

Opioids continue to be recommended and used, despite evidence of a negative association with outcomes in CLBP, including function and productivity and an increased likelihood of substance use disorders.

In number of relevant issues:such“pathological pain states”, nociception is not the sole target, but also suffering, dysfunction, mood states, psychosocial factors and dependence on the health system. Then opioid use is less likely to improve analgesia and even less to yield psychological or functionalimprovement.

Several investigations have identified drug abuse in 18%

to 41% of patients receiving opioids for chronic pain.36-40 The prevalence of lifetime substance use disorders range from 36% to 56%, with an estimate of 43% current substance use disorders and 5% to 24% of the patients with aberrant medicationtakingbehaviours.

Fattori di Rischio per l’Abuso e la Dipendenza number of relevant issues:

Storia di abuso di sostanze

Disturbi mentali

Storia di dolori multipli

Genere maschile

Giovani adulti

Prescrizioni di > 90gg


Programma multidisciplinare

Valutazione dolore, QoL, funzionamento

Supporto psicologico-occupazionale




Spiegazioni esaustive dei rischi

A breve e lungo termine

Unintentional overdose death related to an number of relevant issues:opioid analgesic

9 persons are admitted for substance abuse treatment

35 visit ER

161 report drug abuse or dependence

461 report nonmedical uses of opioid analgesics

It has been shown that from 1997 through 2007, there was a seven fold increase in the number of prescriptions foropioids.

The pharmaceuticalindustryaggressivelymarketed long-acting opioids for chronic pain relying on 2 erroneous facts:

That medical management with opioids is the recommended solution for undertreated chronic pain

That the use of long-acting formulations decreases incidences of prescription opioid abuse.

The principles of opioid management in acute pain and cancer pain were transferred to the chronicpain arena.

JAMA 2000, 283: 1710-1714: ”Increasedopioid use is not associated with deleterious healthconsequences”.

Approximately seven fold increase in the number of prescriptions two-thirdsofthe panel responsible for writing guidelines for the use of opioids for chronic pain for the American Academy of Pain Medicine (AAPM) and American Pain Society (APS) had conflicts of interest with the opioid pharmaceutical industry.

The investigationannouncedby the Senate in reference to conflicts of interest in preparation of opioid guidelines and promotion of opioid usage, have resulted in abandonment of the American Pain Foundation on May 10, 2012, which was a pivotal organization in promoting opioid use.

Rischi del trattamento con oppioidi nel lungo termine: seven fold increase in the number of prescriptions

Dipendenza fisica

Sviluppo di tolleranza

Iperalgesia indotta da oppioidi

Abuso e Dipendenza

Deficit cognitivi

Ipogonadismo (Disfunzioni sessuali, osteoporosi, depressione, fatica)

Alterazioni del sistema immunitario (attraverso il sistema ipotalamo-ipofisi-surrene)

riduce la produzione di anticorpi

riduce l’attività delle cellule Natural Killer

riduce l’espressione di citochine

riduce l’attività fagocitaria

Opioid seven fold increase in the number of prescriptions usefor the management ofpain in fibromyalgiaisstronglydiscouraged and isnotrecommendedbyanycurrentguideline.

women seven fold increase in the number of prescriptions couldbe at higherriskfor the negative medicaland psychologicaleffectsofopioidsbecausetheyhavemore persistentpainthanmen, and maybeprescribedopioidsmore often and at higherdosesthanmen

multiple psychophysiologicalfactorsmaycontributetocertainrisks and consequencesofchronicopioidtherapy

risksin pregnancy and breast-feeding

asin men, risksthat are uniqueto women mayincreaseconcomitantlywithgreaterexposuretoopioids(in termsoffrequency and dosage)

asin men, risksfor women appeartovary at differentages.

GRAZIE PER LA VOSTRA ATTENZIONE seven fold increase in the number of prescriptions